Active surveillance of prostate cancer

Prostate Cancer Diagnosis Just Got Easier with CE Mark Certification of Lucida Medical's New AI Software

Retrieved on: 
Monday, October 23, 2023
Sale, Trial of the century, MRI, Radiology, Active surveillance of prostate cancer, CE, Certification, Entrepreneurship, Prostate cancer, Software, NHS, Life expectancy, Hospital, Biopsy, IRCCS, European Society of Radiology, Cancer, CE marking, Patient, Diagnosis, Prostate, Lancet, Medical imaging, EU

CAMBRIDGE, United Kingdom, Oct. 23, 2023 /PRNewswire/ -- Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™).

Key Points: 
  • CAMBRIDGE, United Kingdom, Oct. 23, 2023 /PRNewswire/ -- Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™).
  • Built with leading clinicians and UK NHS hospitals, the CE mark means the software can now benefit patients across Europe.
  • Using AI, Pi™ analyses the MRI and is fully integrated into the radiologist's workflow, targeting key issues of variability, radiologist time, and diagnostic accuracy in prostate cancer.
  • As the most common cancer in men, each year, prostate cancer gains 1.4 million diagnoses and claims 375,000 lives.

Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer

Retrieved on: 
Tuesday, September 26, 2023
Male, Partnership, GPS, University, Prostate cancer, Genomics, Cancer, Risk assessment, Prompt, Research, Prostate, Doctor of Philosophy, HIV disease progression rates, Patient, United Kingdom, Active surveillance of prostate cancer, University of Oxford, Dairy, Medical imaging

IRVINE, CA, and HERSTAL, BELGIUM – September 26, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – September 26, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer.
  • We are excited to collaborate with mdxhealth to validate the GPS test's potential to enhance risk assessment in men diagnosed with localized prostate cancer."
  • The outcomes of this collaboration can pave the way for more tailored and effective treatments for patients with localized prostate cancer.
  • We firmly believe that our Genomic Prostate Score test holds the potential to accurately predict disease progression in patients undergoing treatment for localized prostate cancer.”

September is Prostate Cancer Awareness Month

Retrieved on: 
Friday, September 1, 2023
Prostate cancer, AUA, Skin cancer, Cancer, Lung cancer, American Urological Association, Risk, Prostate, Death, Incidence, Active surveillance of prostate cancer, Disease, Dairy, MD

"Prostate cancer is the most commonly diagnosed cancer in men next to skin cancer," said Harris M. Nagler, MD, President of the Urology Care Foundation.

Key Points: 
  • "Prostate cancer is the most commonly diagnosed cancer in men next to skin cancer," said Harris M. Nagler, MD, President of the Urology Care Foundation.
  • Since 2014, the incidence rate of prostate cancer has increased by 3% per year overall and by about 5% per year for advanced-stage prostate cancer.
  • Talk to your doctor about prostate cancer screening if you are age 40 to 54 years and:
    Black men are 17x more likely to be diagnosed with prostate cancer and are 2.1x more likely to die from prostate cancer than white men.
  • For everything you need to know about prostate cancer, check out the Urology Care Foundation's Prostate Cancer Info Center , and scroll through its Twitter, Facebook and Instagram platforms for free prostate cancer resources, including fact sheets, podcasts, videos and more.

Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test

Retrieved on: 
Wednesday, August 9, 2023
Insurance, GPS, Prostate cancer, Hospital, Genomics, Cancer, Prostate, Cigna, Medicare, Active surveillance of prostate cancer, Patient, Diagnosis, PSA, Health insurance, Medical imaging, Select

Expansion of coverage with Cigna now includes full menu of Company’s precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage

Key Points: 
  • Expansion of coverage with Cigna now includes full menu of Company’s precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage
    IRVINE, CA, and HERSTAL, BELGIUM – August 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced that Cigna has expanded commercial and Medicare Advantage coverage to include the Company’s Select mdx for Prostate Cancer test.
  • With the addition of Select mdx, Cigna will now provide insurance coverage across mdxhealth’s full menu of precision diagnostic cancer tests, including its Confirm mdx and Genomic Prostate Score (GPS) tests.
  • Contracted coverage with Cigna for the Select mdx test is expected to take effect in Q4 of this year.
  • There are approximately 3 million prostate cancer screenings conducted in the U.S. which show elevated PSA results.

Study Sheds Light on Persistent Racial Disparities in Prostate Cancer Care in the United States

Retrieved on: 
Tuesday, June 29, 2021
Anatomy, Prostate cancer, Cancer, Branches of biology, Prostate, Prostate cancer screening, Active surveillance of prostate cancer

This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.

Key Points: 
  • This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.
  • From these national databases, they identified all men diagnosed with prostate cancer and characterized them by their life expectancy (based on their other medical diagnoses) and the severity of their prostate cancer.
  • Prostate cancer remains the second-leading cause of cancer death among American men, with more than 34,000 dying annually from the disease.
  • The U.S. National Cancer Institute estimates that 248,000 men will be diagnosed with prostate cancer in 2021, most in its earliest stages.

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Thursday, June 24, 2021
Cancer, Anatomy, Branches of biology, Prostate cancer, Histopathology, Prostate, Active surveillance of prostate cancer, Larry Goldenberg

The study , led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal.

Key Points: 
  • The study , led by a team of renowned prostate cancer researchers, has been published in Clinical Cancer Research, a high impact journal.
  • This treatment induced neuroendocrine prostate cancer is becoming more prevalent with increasing use of ARSis and is associated with very poor patient clinical outcomes.
  • Prostate cancer is the second most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide.
  • Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents.

NBA Legend and Prostate Cancer Survivor Kareem Abdul-Jabbar Featured in New Public Service Announcement by the Prostate Cancer Foundation and NBA Cares Launched on Father's Day

Retrieved on: 
Monday, June 21, 2021
Prostate cancer, Anatomy, Cancer, Clinical medicine, Prostate Cancer Foundation, Prostate, Prostate Cancer Foundation of Australia, Active surveillance of prostate cancer

One in eight men will be diagnosed with prostate cancer in his lifetime, but for Black men, one in seven will develop the disease.

Key Points: 
  • One in eight men will be diagnosed with prostate cancer in his lifetime, but for Black men, one in seven will develop the disease.
  • Prostate cancer is the most common non-skin cancer in men in the U.S., and the fourth most common tumor diagnosed worldwide.
  • The Prostate Cancer Foundation (PCF) is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research.
  • The Prostate Cancer Foundation research now impacts more than 70 forms of human cancer by focusing on immunotherapy, the microbiome, and food as medicine.

NorthShore University HealthSystem and GoPath Laboratories Partner to Offer the Most Comprehensive Inherited Risk Assessment for Prostate Cancer with PROSTATENOW™

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Biology, Life sciences, Histopathology, Prostate cancer, Biotechnology, Cancer, Single-nucleotide polymorphism, Active surveillance of prostate cancer, Prostate Cancer Health Disparities in African Americans

The test, which features the Genetic Risk Score developed by NorthShore, is available online at https://gopathgenetics.com/prostatenow/ and addresses evidence that genetics are commonly overlooked when assessing prostate cancer risk.

Key Points: 
  • The test, which features the Genetic Risk Score developed by NorthShore, is available online at https://gopathgenetics.com/prostatenow/ and addresses evidence that genetics are commonly overlooked when assessing prostate cancer risk.
  • "Combining all three tools provides the most comprehensive inherited risk assessment for patients and their families."
  • Most prostate cancer patients and their families can benefit from germline testing -- recently recommended by new National Comprehensive Cancer Network (NCCN) guidelines.
  • PROSTATENOWTMincludes all known prostate cancer susceptible genes and more than 100 prostate cancer risk associated single nucleotide polymorphisms (SNPs) for calculating genetic risk score in multiple races.

Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Anatomy, Prostate cancer, Clinical medicine, Histopathology, Prostate, Cancer, Glutamate carboxypeptidase II, Prostate cancer screening, Active surveillance of prostate cancer

Accessibility to this valuable examination will increase across the Czech Republic, as previously it was limited to one single pioneer hospital in Pilsen.

Key Points: 
  • Accessibility to this valuable examination will increase across the Czech Republic, as previously it was limited to one single pioneer hospital in Pilsen.
  • The Czech Republic is the first European country to grant broad patient access to PSMA imaging, and we look forward to working with our distribution partner THP Medical Products to ensure this state-of-the-art imaging modality is available to all men in the Czech Republic living with prostate cancer.
  • Prostate cancer is the second most common cancer in men following skin cancer, with approximately 1.4 million men diagnosed with prostate cancer annually worldwide.4 While meaningful advances in the treatment of prostate cancer have occurred in recent years, more than 375,000 men still die from their disease each year.
  • The incidence of prostate cancer continues to increase, with the highest rates of the disease occurring in the United States, Canada, Europe and Australia and New Zealand.

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

Retrieved on: 
Friday, February 12, 2021
Cancer, Histopathology, Prostate cancer, Clinical medicine, Medicine, Oncology, Active surveillance of prostate cancer

According to estimates by the American Cancer Society, 248,530 new cases of prostate cancer are expected to be diagnosed this year in the U.S.

Key Points: 
  • According to estimates by the American Cancer Society, 248,530 new cases of prostate cancer are expected to be diagnosed this year in the U.S.
  • The Prolaris test can more accurately predict the aggressiveness of the cancer allowing for more precise treatment and avoidance of more intense therapies with a patients parallel morbidities.
  • There are many viable treatment paths for men with prostate cancer, said Dr. Tward.
  • This new data helps distinguish the most appropriate personalized treatment path for each patient based on how their specific tumor is behaving.